State-of-the-Art Paper
Biomaterials for the Treatment of Myocardial Infarction: A 5-Year Update

https://doi.org/10.1016/j.jacc.2011.11.001Get rights and content
Under an Elsevier user license
open archive

The first review on biomaterials for the treatment of myocardial infarction (MI) was written in 2006. In the last 5 years, the general approaches for biomaterial treatment of MI and subsequent left ventricular remodeling remain the same, namely, left ventricular restraints, epicardial patches, and injectable therapies. Nonetheless, there have been significant developments in this field, including advancement of biomaterial therapies to large animal pre-clinical studies and, more recently, to clinical trials. This review focuses on the progress made in the field of cardiac biomaterial treatments for MI over the last 5 years.

Key Words

biomaterial
cardiac patch
injectable
left ventricular remodeling
left ventricular restraint
myocardial infarction

Abbreviations and Acronyms

bFGF
basic fibroblast growth factor
ED
end-diastolic
EF
ejection fraction
ES
end-systolic
FS
fractional shortening
LV
left ventricle
MI
myocardial infarction
MSC
mesenchymal stem cell
PEG
poly(ethylene glycol)
SIS
small intestinal submucosa
VEGF
vascular endothelial growth factor

Cited by (0)

Ms. Rane has reported that she has no relationships relevant to the contents of this paper to disclose. Dr. Christman is the cofounder of Ventrix Inc. D. Geoffrey Vince, PhD, served as the Guest Editor for this paper.

Copyright © 2011 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.